Cadmium is a widely distributed, toxic trace metal. Cadmium poisoning causes damage to major organ systems, and in humans this leads to Itai-Itai disease (1, 4 . This nonessential transition metal is also carcinogenic (3) (4) (5) and is deleterious to the reproductive process, causing retardation of growth, sterility, teratogenic, and embryotoxic effects (6) (7) (8) . In rodents, spermatogenesis has long been known to be highly susceptible to cadmium. In sensitive strains of mice, the testes undergo necrosis after exposure to cadmium (9, 10) . Likewise, injection of pregnant female mice with a sublethal dose of cadmium on the day of blastocyst implantation (day 4) significandy reduces pregnancy rate by midgestation (11) . Cadmium exerts embryotoxic effects on preimplantation embryos in vitro (12, 13) , and these effects are particularly dependent on the stage of embryonic development, with the blastocyst being the most sensitive to cadmium toxicity (11, 14) . However, cadmium also exerts toxic effects on the female reproductive tract and can delay the onset of implantation (11) . After implantation, the deciduum, placenta, and visceral yolk sac may serve to protect the embryo by restricting the passage of cadmium from the mother, but exposure to cadmium during the organogenic period can induce limb bud and craniofacial defects (6, 7) . Mechanisms Metallothioneins (MT) are a family of cysteine-rich cadmium-binding proteins (15) whose genes are transcriptionally activated by cadmium (16) . Because MTs have been shown to protect against cadmium toxicity in cultured cells (17, 18) and in mice (19) (20) (21) they are prime candidates for protecting against toxic effects of cadmium on reproductive processes.
Several strains of mice that overexpress MT have been created using a minimally mutated MT-I (MT-Ij gene under the control of 1.8-kb of the mouse MT-I promoter and flanked by the MT-I/MT-I] locus control regions (LCR) (22) . In these mice, the MT-I*transgene is expressed in a copy-number-dependent, integration-siteindependent manner, and developmental expression appears to mimic the endoge nous gene. We examined one of these transgenic mouse strains and reported tha MT is overexpressed in most major organ (23) . In this study we documented th( level of expression and tissue-specific distri bution of MT in reproductive organ (uterus and testes) of male and femalb transgenic and control mice from thi strain and evaluated the role of MT in pro tection against cadmium-induced testiculai damage and early pregnancy failure.
Methods
Animals. All experiments involving ani mals were conducted in accordance witl National Institutes of Health standards for the care and use of experimental animals. The transgenic mice used in these studies were derived from heterozygous males that carry 56 copies of minimally mutated MT-I (MT-Ij gene on the B6/SJL F1 background (22) . These mice were outbred to CD-1 females (Charles River Breeding Laboratories, Raleigh, North Carolina), and the heterozygous male offspring were selected. These heterozygous males were bred with CD-1 females, and experiments were performed using the transgenic and nontransgenic (control) littermates from this breeding. We identified transgenic and control mice by DNA slot blot analysis. For experiments involving pregnant animals, virgin females of the indicated strain (48-68 days old) were mated with males of the indicated strain, and the morning a vaginal plug was detected was defined as f day 1 of pregnancy. To determine the effect of cadmium on pregnancy, we injected cadmium on s the morning of day 4 and assessed pregnany cy success on day 14 as described (11) . The e effect of cadmium on the testes was deter--mined by histological examination 24 and I 48 hr after cadmium injection. e MT determination. MT was determined a by the cadmium-hemoglobin exchange assay as described (24) . For convenience, LI tissue samples were frozen in liquid nitrogen and stored at -700C before analysis. 
IS
Isolation of RNA and Northern blot hybridization. Tissues were frozen in liquid nitrogen and stored at -700C before RNA extraction. RNA was prepared by an initial guanidine thiocyanate (GTC)/phenol/chloroform extraction as described (25) , followed by sodium dodecyl sulfate (SDS)/phenol/chloroform extractions (26, 27) . Poly A+ RNA was isolated as described by Aviv and Leder (28) , using total RNA and oligo(dT) cellulose (Collaborative Biochemicals, Bedford, Massachusetts; 20 mg total RNA/0.5 g cellulose).
RNA was size fractionated by formaldehyde-agarose gel electrophoresis and Northern blotted to nylon membranes (29) . Northern blots were prehybridized, hybridized with a mouse MT-I 32P-labeled cRNA probe (specific activity = 2 x 109 dpm/pg), and washed (26, 29, 30 as described previously (30, 33 (35) . Therefore, the peptide was acetylated on the aminoterminal methionine after synthesis and the C-terminal cysteine carboxyl group was converted to an .amide. Cysteine residues corresponding to amino acids 5, 7, and 13 were substituted with alanine. For injection, this peptide was conjugated to keyhole limpet hemocyanin through the C-terminal cysteine sulfhydryl group.
Immunohistochemistny and histology.
Immunolocalization of MT-I was performed essentially as described (27, (36) (37) (38) . Briefly, uteri were excised, cleaned of fat, and either fixed intact in Bouin's solution or implantation sites were grossly dissected from interimplantation regions and then fixed in Bouin's. Testes were removed from mature males (>68 days old) after perfusion fixation with Bouin's and cut into small pieces which were further fixed in Bouin's. Fixed tissues were dehydrated and embedded for paraffin sections. Paraffin sections (7 pm) were incubated in 10% normal goat serum for 10 min before incubation with primary antibody (1:500 dilution) for [16] [17] [18] [19] [20] 
Results

MT-I mRNA Levels
To determine whether MT transgenes are overexpressed in the testes and peri-implantation uterus of transgenic animals, total RNA was prepared from these tissues and MT-I mRNA levels were quantitated by solution hybridization. This assay employed an oligonucleotide that detected both endogenous MT-I and transgene-derived MT-I* transcripts. MT-I mRNA levels were elevated 8.3-fold in total RNA from the testes of transgenic compared with control nontransgenic littermates (Fig. 1A) . In the uterus, at sites of embryo implantation, MT-I mRNA levels were elevated 20.2-fold on day 6 and 8.6-fold on day 8 compared to levels in control mice. During this period, days 6-8, there is massive growth of the deciduum, which surrounds the embryo and actively expresses the entire MT gene locus (33, 40) . Northern analysis showed that MT-I mRNA levels in transgenic mice are highest in the implantation sites/deciduum compared to the interimplantation regions of the uterus (Fig. 1B) 
Determination of MT Levels in Tissues
To determine whether MT accumulates to higher levels in the testes and peri-implantation uterus of transgenic mice, MT was quantitated in heat-stable tissue extracts using the cadmium-hemoglobin exchange assay (24) . Cadmium-binding was increased significantly in all the major organs examined from transgenic mice compared with those from control mice (Fig. 3) , as expected from our previous studies (23) . In the transgenic testes, MT levels were 5.2-fold higher than in control mice, and in uterine implantation sites MT levels were 8.7-fold higher on day 6 and 2.6-fold higher on day 8 than levels in control mice. As predicted by increases in MT-I mRNA between day 6 and day 8, decidual MT levels correspondingly increased during this period in both transgenic and control mice (Fig. 3) . In general, the increases in MT-I mRNA in the transgenic compared to control mice (Fig. 1) are accompanied by increases in heat-stable cadmium-binding activity in these tissues.
Immunohistochemical Localization of MT
Expression of the mouse MT genes is cell specific in the pern-implantation uterus (33, 40) and in the testes (41 Uterine implantation sites Figure 3 . Determination of steady-state levels of MT in tissues of transgenic and control female and male mice. MT was determined by the cadmium-hemoglobin exchange assay (24) in heat-stable extracts prepared from the tissues. Uterus, deciduum, liver, kidney, and pancreas were obtained from female transgenic and control mice. Day-4 uterus represents MT in the whole uterus, whereas day-6 uterus represents MT in the implantation sites, and day-8 deciduum represents MT in deciduum dissected free of the myometrium. Testes were isolated from mature breeding males. Data represent the means ± SDs of at least three independent assays of tissues pooled from three animals each. For each tissue the transgenic MT level was significantly different from control (p < 0.001, Student's t-test).
mine whether the MT-I* gene is also expressed in a cell-specific manner in these transgenic mice, MT-I was immunolocalized in the day-4 uterus, day-6 and day-8 deciduum, and in the testis (Fig. 4) using an anti-MT-peptide antisera. Our studies of CD-1 mice demonstrated that abundant MT-I mRNA is found in uterine luminal and glandular epithelium on day 4 and in the secondary decidual zone on days [6] [7] [8] (40) . MT-I immunoreactivity was also localized only to these locations in uterine sections from control mice (Fig. 4A) . Specificity of the antisera was confirmed using nonimmune sera (not shown) and by antibody neutralization (Fig. 4) before immunostaining. In uterine sections from transgenic mice, MT immunostaining was also restricted to the same cell types as in nontransgenic mice (Fig. 4B ), but the immunostaining was notably more intense.
Sections from the testes of control mice displayed only weak MT-I immunoreactivity confined to one or two Leydig cells per field of view (Fig. 5A) . Using preabsorbed antibody eliminated this staining (Fig. 5B) . In transgenic animals, MT immunoreactivity was also confined to Leydig cells (Fig.  5D, E (11) (12) (13) . We reported that subcutaneous injection of a sublethal dose of cadmium (38 pmol/kg) on day 4 of pregnancy resulted in loss of pregnancy, accompanied by a loss in viability of blastocysts flushed from the uterus on day 5 (11) . However, maternal effects of cadmium were also noted in those -studies and were likely to play a role in the loss of pregnancy. To determine if cell-specific overexpression of MT would protect against cadmiuminduced pregnancy failure, transgenic and control mice were given a single subcutaneous injection of cadmium on the morning of day 4 of pregnancy, before blastocyst implantation, and pregnancy was assessed by gross dissection of the uterus on day 14 (Table 1) . Mice used in these experiments were divided into three groups based on expression of MT: group 1 mice had normal maternal and embryonic MT gene expression and consisted of nontransgenic females (CD-1 or control) mated with CD-1 males. Group 2 mice had normal maternal MTgene expression but overexpression of embryonic MT and consisted of CD-I females mated with heterozygous transgenic males (50% transgenic embryos). Group 3 mice had maternal and embryonic overexpression of MTand consisted of heterozygous transgenic females mated with CD-1 males (50% transgenic embryos).
In untreated mice, 90-100% of the females that had a vaginal plug on day 1 were found to be pregnant at mid-gestation (day 14), and there were no differences among transgenic, control, and CD-1 females in the number of implantation sites per uterus or the percentage of embryos that had died and were resorbed by day 14 ( Table 1) . To examine the effects of cadmium on pregnancy, three doses (30, 40, and 45 pmol Cd/kg body weight) were administered on day 4 to mice in each of these groups. Each of these doses of cadmium reduced the pregnancy rate similarly in all three groups of mice. An injection of 30 uimol Cd/kg slightly reduced the pregnancy rate (to 80-90%) in each group, but had no effect on the number of implantation sites per uterus, the day-14 fetal weight, or embryo resorption rate. In contrast, an injection of 40 pmol Cd/kg resulted in a sharp dedine in pregnancy rate (46-62%) in all three groups (Table 1 ). In each experiment the pregnancy rate was consistently higher in mice with maternal and embryonic overexpression of MT (group 3) than in the other groups of mice. However, there were no remarkable differences between the three groups of mice with regard to the effects of cadmium on pregnancy rate.
Under these experimental conditions, 40 pmol Cd/kg was at the low end of the steep dose-response curve for lethality for each of these groups of mice ( The rodent testis is highly sensitive to the toxic effects of cadmium (9, 10, 42) , and necrosis occurs after the administration of cadmium at levels well below those that cause liver or kidney damage. Transgenic or control male mice were injected with a single subcutaneous dose of cadmium at 7.5 or 10 pmol/kg, and 24 hr or 48 hr later the testes were recovered and examined histologically (Fig. 6 ). The histology of the testis 48 hr after an injection of 7.5 pmol Cd/kg was unchanged in both transgenic and control mice (Fig. 6A,B) . However, 24 hr after an injection of 10 pmol Cd/kg, alterations in the seminiferous epithelium were apparent (Fig. 6C,D) and by 48 hr extensive testicular necrosis, edema, and sloughing of the seminiferous epithelium had occurred in both transgenic and control mice (Fig. 6E,F) . These results demonstrate that overexpression of MTaffords no apparent protection against cadmiuminduced testicular necrosis. bDetermined as the number of animals that died between day 4 and day 14 of pregnancy, inclusive, divided by the total number of animals injected with cadmium in that group.
cDetermined as the number of day 14 pregnant animals divided by the total number of mice alive on day 14. dData represent the means ± SDs.
Discussion
The transgenic mice used in this study have stable integration of 56 copies of an MT-I* transgene with 1.8 kb of the MT-I promoter and flanked by 10 (44) . Interestingly, primary hepatocytes from this transgenic strain that overexpresses MT are about 7-fold more resistant to cadmium toxicity in vitro. Thus, large differences between transgenic and control mice in their resistance to cadmium toxicity were predicted based on studies of cultured cells, but studies of these transgenic mice demonstrate that within the physiological context of the animal, overexpression of MT affords little protection from cadmium toxicity.
In contrast, studies of mice in which the MT-I and MT-II genes have been disrupted suggest a significant increase in sensitivity to cadmium-induced hepatotoxicity and lethality (20, 21) . Although no detailed dose-response curves for cadmium toxicity have been reported, studies of these mice reveal clear increases in cadmium toxicity. Control mice can tolerate 14 daily injections of 10 pmol Cd/kg, whereas the knockout mice succumb after 2-4 days, depending on sex (21) . Embryonic fibroblasts from these knockout mice are also 2-to 3-fold more sensitive to cadmium in vitro than are control fibroblasts (45) . Therefore, MT can serve a protective function against cadmium in vivo, but overexpression of MT in a proper cell-specific manner does not significantly augment that protective function.
It is perhaps surprising that overexpression of MT at its normal sites of synthesis in the mouse did not effectively protect early pregnancy or spermatogenesis from cadmium toxicity by scavenging cadmium from the serum. After acute exposure to cadmium, the liver can sequester up to 60% of the cadmium challenge (46, 47) , and hepatotoxicity is closely associated with cadmium-induced mortality (48, 49) . MT in the transgenic liver was significandy elevated, and the liver is considered responsible for cadmium detoxification. Despite these considerations, no protection was afforded these reproductive processes, and low levels of cadmium caused testicular necrosis in both the control and transgenic mice.
In the testes of nontransgenic animals, MT immunostaining using an antipeptide antisera was confined to a few Leydig (41) . Pachytene spermatocytes and round spermatids isolated from these transgenic mice also contained high levels of MT-I mRNA, and the vast majority of it was derived from the MT-I* transgene (data not shown). The lack of MT immunostaining in these germ cells is con- sistent with the suggestion that MT accumulation is controlled primarily by posttranscriptional mechanisms in male germ cells (41) .
Some inbred strains of mice show remarkable resistance to testicular necrosis produced by lethal doses of cadmium (53, 54) , and this is attributed to the autosomal recessive cdm gene (55) . Although it has been proposed that in the rat, testicular susceptibility to cadmium is the result of the low expression of MT genes (56, 57) , the studies reported here suggest that the cdm gene is a far more important genetic determinant for testicular sensitivity to cadmium than is the level of testicular MT. Overexpression of MT in the testes was not sufficient to protect from cadmiuminduced testicular damage. Leydig cells are not required for the effects of cadmium on the testes (58) , but elevation of MT in Leydig cells present in the interstitium of the testes might be expected to protect the germ cells because the interstitium is the major site of cadmium accumulation in the testes (59, 60) . Collectively, these studies establish that MT in the interstitium is of limited use in preventing testicular injury after cadmium exposure.
Our earlier studies indicated that pregnancy failure after cadmium exposure on day 4 may have resulted from a direct embryotoxic effect on the blastocyst (11). However, the results obtained here, using a larger number of mice, strongly suggest that effects of cadmium on the mother play the key role in the maintenance of pregnancy. Although transgenic blastocysts from these mice display marked elevation in MT (approximately 10-fold) compared to control blastocysts and more resistant to Cd toxicity in vitro (43) , studies reported here establish that transgenic embryos have no selective advantage in vivo after maternal exposure to cadmium under these experimental conditions. Pregnancy failure after cadmium exposure on day 4 may result from effects on the uterus; for example, on uterine receptivity for implantation. We previously reported that cadmium can cause a delay in the initiation of implantation (localized sites of increased uterine vascular permeability) in mice (11) . After implantation, cadmium has restricted access to the embryo, perhaps due to the high levels of MT expressed in the deciduum and visceral yolk sac (6, 7, 61) . Despite increased expression of MT in these tissues, the transgenic mice were not significantly protected from cadmium toxicity during the peri-implantation period.
Studies of cadmium toxicity in these transgenic mice that overexpress MT are consistent with the likelihood that cadmiVolume 104, Number 1, January 1996 * Environmental Health Perspectives I 7.2-! ! , . f l f i um exerts its lethal effects, in part, on cells that do not overexpress MT. It has been suggested that hepatic endothelial cells are a target of cadmium toxicity and that this may account for strain differences in susceptibility (62. Cadmium-induced testicular damage has also been suggested to result from injury to the vasculature, which leads to ischemia and death of seminiferous epithelium (63) (64) (65) . In that regard, the process of blastocyst implantation involves highly localized increases in vascular permeability at the sites of embryo implantation. Immunolocalization of MT in these transgenic mice did not suggest enhanced accumulation in endothelial cells of the testes or uterus. The ovary and placenta are also suceptible to cadmium toxicity (6), but dosages of cadmium that disrupt the testes had little effect on the establishment and maintenance of pregnancy.
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